

type 2 diabetes using SGLT2 inhibitors versus other glucose-lowering drugs: a retrospective cohort study. *Am J Kidney Dis.* 2020;76:471–90.

7. Gilbert RE, Thorpe KE. Acute kidney injury with sodium-glucose co-transporter-2 inhibitors: a meta-analysis of cardiovascular outcome trials. *Diabetes Obes Metab.* 2019;21:1996–2000.
8. Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. *Lancet Diabetes Endocrinol.* 2019;7:845–54.
9. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, editors. *Cochrane Handbook for Systematic Reviews of Interventions* version 6.2 (updated February 2021). Cochrane, 2021. Available from: <http://www.training.cochrane.org/handbook>.
10. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ.* 2019;366:14898.

Dimitrios Patoulas<sup>a,\*</sup>, Christodoulos Papadopoulos<sup>b</sup>, Fotios Siskos<sup>a</sup>, Michael Doumas<sup>a,c</sup>

<sup>a</sup> Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, General Hospital “Hippokraton”, Greece

<sup>b</sup> Third Department of Cardiology, Aristotle University of Thessaloniki, General Hospital “Hippokraton”, Greece

<sup>c</sup> Veterans Affairs Medical Center, George Washington University, Washington, District of Columbia, United States

\*Corresponding author.

E-mail address: [dipatoulas@gmail.com](mailto:dipatoulas@gmail.com) (D. Patoulas).

0211-6995/© 2021 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

<https://doi.org/10.1016/j.nefro.2021.05.012>

## Acute renal failure as a debut manifestation in Still’s disease

### Insuficiencia renal aguda como manifestación inicial en la enfermedad de Still

Dear Editor,

Adult Still’s disease (ASD) is a systemic inflammatory disease of unknown etiology. Renal involvement in ASD is a rare and rarely reported manifestation in the literature. This report presents an atypical case of ASD with acute renal failure.

A 39-year-old male with arterial hypertension treated with Ramipril 10 mg was admitted to the Emergency Department (ED) with a fever of up to 39 °C, right laterocervical edema, dysphagia, and odynophagia the last four days. He started treatment with Amoxicillin-Clavulanate before consultation in the ED. The patient did not report country outings or recent trips. He highlighted an infestation of rodents in his building. The patient denied consuming alcohol, tobacco and other drugs, or mushrooms, herbal products, or other substances that could have caused liver damage.


Physical examination revealed mild jaundice, a temperature of 38 °C, non-adhered right laterocervical lymphadenopathy of 1–2 cm, enlarged tonsils with discrete whitish plaques on their surface, and a macular and itchy rash on the upper trunk and forearms. Laboratory tests at ED showed: procalcitonin 1.10 ng/ml, urea 69 mg/dL, creatinine 2.79 mg/dL, sodium 135 mmol/L, potassium 4.5 mmol/L, chlorine 98 mmol/L, GPT 114 U/L, CK 233 U/L, Amylase 35 U/L, C reactive protein (CRP) 286.9 mg/L, leukocytes 15,430/mcL (neutrophils 13,740/mcL), prothrombin activity 63%. Abdominal ultrasound and chest X-ray were normal. The patient presented the day after admission: total bilirubin 9 mg/dL, direct bilirubin 8.4 mg/dL, GGT 143 IU/L, and Alkaline Phosphatase 267 IU/L. Leukocytosis

reached 33,000/mcL with 92% polymorphonuclear cells. The rise in ferritin levels was remarkable with 4.104 mcg/mL. During admission, the patient presented a rapid onset acute renal failure with anuria. The renal function worsened with a creatinine of 10.36 mg/dL. This clinical course led to hemodialysis therapy from the second day of admission.

Immunoglobulin A level was 479 mg/dL. C3, C4, Anti-streptolysin O, antinuclear antibodies, nuclear extractible antigen antibodies, anti-DNA antibodies, neutrophil anti-cytoplasmic antibodies were normal or negative. Interleukin-6 was 148 pg/mL. Plasma protein electrophoresis was compatible with an acute inflammatory process.

Nasopharyngeal swab for Polymerase Chain Reaction for SARS-CoV2 and pharyngeal swab for *Streptococcus pyogenes* were both negative. Urine and blood cultures were negative. Serologic studies ruled out acute infection by Cytomegalovirus, Epstein-Bar virus, Measles, Q fever, Leptospira, hepatitis A and B viruses, Human Immunodeficiency Virus, and parvovirus B19. A computed tomography (CT) scan showed a slightly enlarged 15-cm spleen. A Positron Emission Tomography-CT scan was normal.

Finally, a renal biopsy showed an acute tubulointerstitial inflammatory infiltrate with some ruptured tubule and isolated eosinophils associated with a dense lymphoplasmacytic infiltrate and a mesangial deposit anti-IgA (++) and minimal anti-C3, all of which was compatible with IgA mesangial nephropathy and acute tubulointerstitial nephritis (Fig. 1). However, there was an absence of intratubular erythrocyte casts or crescents in the biopsy.



**Fig. 1** – Renal biopsy images: (A) Image showing glomeruli with mostly normal characteristics; (B) image showing acute interstitial infiltrate with a predominance of lymphocytes and eosinophils together with some ruptured tubules; (C) Image showing positivity of anti-IgA immunofixation.

**Table 1** – Diagnostic criteria of ASD.

Criteria of Yamaguchi et al. [4] <sup>a</sup>	
<p><i>Major criteria:</i></p> <ul style="list-style-type: none"> <li>- Fever <math>\geq 39^{\circ}\text{C} \geq 1</math> week</li> <li>- Arthralgias/Arthritis for 2 or more weeks</li> <li>- Typical evanescent rash</li> <li>- Leukocytosis <math>\geq 10,000/\text{mm}^3</math> with <math>\geq 80\%</math> polymorphonuclear</li> </ul>	<p><i>Minor criteria:</i></p> <ul style="list-style-type: none"> <li>- Odynophagia</li> <li>- Lymphadenopathy</li> <li>- Splenomegaly</li> <li>- Alteration of liver function tests</li> <li>- Rheumatoid factor and ANA negatives</li> </ul>
Criteria of Fautrel et al. [5] <sup>b</sup>	
<p><i>Major criteria:</i></p> <ul style="list-style-type: none"> <li>- Spiking fever <math>\geq 39^{\circ}\text{C}</math></li> <li>- Arthralgia</li> <li>- Transient skin rash</li> <li>- Odynophagia</li> <li>- Polymorphonuclear cells <math>&gt; 80\%</math></li> <li>- Glycated ferritin <math>\leq 20\%</math></li> </ul>	<p><i>Minor criteria:</i></p> <ul style="list-style-type: none"> <li>- Maculopapular rash</li> <li>- Leukocytosis <math>&gt; 10,000/\text{mm}^3</math></li> </ul>
<p><sup>a</sup> 5 or more of these criteria, of which at least 2 major criteria, establishes the diagnosis of the disease (sensitivity of 96.2% and specificity of 92.1%). Infections, neoplasms, and other systemic diseases that can simulate an ASD should be excluded.</p> <p><sup>b</sup> 4 or more major criteria or 3 major + 2 minor criteria are needed for diagnosis.</p>	

Our patient meets the criteria of both Yamaguchi and Fautrel for presumptive diagnosis of ASD (Table 1). Corticosteroid treatment was started initially with Prednisone 60 mg/day, and subsequently escalating to 500 mg of 6-Methylprednisolone daily associated with Anakinra at 100 mg/week, causing a rapid and progressive improvement in the general condition and rash, a decrease in the acute phase reactants and leukocytosis, and an improvement in his renal function. The patient recovered normal diuresis and was

discharged with a creatinine of 2.04 mg/dL with proteinuria of 25 mg/dL in basic urine examination. After discharge from the hospital, the patient fully recovers renal function with a creatinine of 1 mg/dL.

Since there are currently no specific diagnostic tests, ASD diagnosis is usually based on the clinical recognition of the entity, always ruling out other possible etiologies such as infections or neoplasms. Among the criteria used for its diagnosis are the Yamaguchi criteria<sup>1</sup> and the Fautrel criteria<sup>2</sup>

(Table 1). Elevated procalcitonin, C-reactive protein, and leukocytosis with neutrophilia could lead the clinician to suspect other etiologies, especially infectious, and diagnostic delay. Serum ferritin or cytokines, such as IL-6, can help diagnosis. The combination that has shown the greatest diagnostic accuracy was serum ferritin > 1000 mcg/L or values five times above the upper limit of normal, together with a fraction of glycated ferritin < 20%. Its sensitivity and specificity are 70.5% and 92.9%, respectively.<sup>3,4</sup>

Still's disease can present more atypical manifestations, such as acute renal failure of rapid onset. Entities associated in previous literature were Amyloidosis,<sup>5</sup> Thrombotic Microangiopathy,<sup>6</sup> IgA Glomerulonephritis,<sup>7</sup> and more recently, cases of collapsing glomerulopathy.<sup>8</sup> However, despite being described in reviews on Still's disease,<sup>9</sup> only one case of interstitial nephritis has been found reported in the consulted bibliography.<sup>10</sup>

Therefore, it is essential to include ASD in the differential diagnoses of acute renal failure accompanied by analytical markers such as elevated IL-6 or ferritin of up to five times its standard value. Early treatment of this disease can lead to the complete recovery of the patient's previous renal function.

## Informed consent

The patient reported here has provided written informed consent for publication of this case report.

## Funding

This work has no funding.

## Conflict of interest

None.

## REFERENCES

1. Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still's disease. *J Rheumatol*. 1992;19:424–30.
2. Fautrel B, Zing E, Golmard JL, Le Moel G, Bissery A, Rioux C, et al. Proposal for a new set of classification criteria for adult-onset Still disease. *Medicine (Baltimore)*. 2020;81:194–200.
3. Feist E, Mitrovic S, Fautrel B. Mechanisms, biomarkers and targets for adult-onset Still's disease. *Nat Rev Rheumatol*. 2018;14:603–18, <http://dx.doi.org/10.1038/s41584-018-0081-x>.
4. Fautrel B, Le Moel G, Saint-Marcoux B, Taupin P, Vignes S, Rozenberg S, et al. Diagnostic value of ferritin and glycosylated ferritin in adult onset Still's disease. *J Rheumatol*. 2001;28:322–9.
5. Oh YB, Bae SC, Jung JH, Kim TH, Jun JB, Jung SS, et al. Secondary renal amyloidosis in adult onset Still's disease: case report and review of the literature. *Korean J Intern Med*. 2000;15:131–4, <http://dx.doi.org/10.3904/kjim.2000.15.2.131>.
6. El Karoui K, Karras A, Lebrun G, Charles P, Arlet JB, Jacquot C, et al. Thrombotic microangiopathy and purtscher-like retinopathy associated with adult-onset Still's disease: a role for glomerular vascular endothelial growth factor? *Arthritis Rheum*. 2009;61:1609–13, <http://dx.doi.org/10.1002/art.24826>.
7. Sayegh J, Besson V, Lavigne C, Croue A, Augusto JF. Necrotizing crescentic immunoglobulin A glomerulonephritis in adult-onset Still's disease. *Clin Exp Nephrol*. 2011;15:978–9, <http://dx.doi.org/10.1007/s10157-011-0546-6>.
8. Arulkumaran N, Reitbock P, Halliday K, Onwubalili J, Jayasena D, Dupont PJ. Adult-onset Still's disease associated with collapsing glomerulopathy. *NDT Plus*. 2010;3:54–6, <http://dx.doi.org/10.1093/ndtplus/sfp114>. Epub 2009 Aug 26.
9. Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Sève P. Adult-onset Still's disease. *Autoimmun Rev*. 2014;13:708–22, <http://dx.doi.org/10.1016/j.autrev.2014.01.058>.
10. Hory B, Dupond J-L, Deprez P, Leconte Des Floris R. Hématuries récidivantes au cours d'une maladie de Still de l'adulte révélée par une péricardite récurrente. *Ses Hôp Paris*. 1977;53:1715–8.

Samuel Blas Gómez<sup>a</sup>, Fernando Mateos Rodríguez<sup>b</sup>,  
María Luisa Illescas Fernández-Bermejo<sup>a</sup>,  
Syonghyun Nam Cha<sup>c</sup>, Julián Solís García del Pozo<sup>b,\*</sup>

<sup>a</sup> Nephrology, Albacete University Hospital Complex, Albacete, Spain

<sup>b</sup> Infectious Diseases, Albacete University Hospital Complex, Albacete, Spain

<sup>c</sup> Pathology, Albacete University Hospital Complex, Albacete, Spain

\* Corresponding author.

E-mail address: [julianeloyolis@gmail.com](mailto:julianeloyolis@gmail.com)  
(J. Solís García del Pozo).

0211-6995/© 2021 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).  
<https://doi.org/10.1016/j.nefro.2021.09.011>